Schedule 14A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549 
SCHEDULE 14A 
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 
Filed by the Registrant     o 
Filed by a Party other than the Registrant     þ 
 
Check the appropriate box:
 
 
 
o 
 
Preliminary Proxy Statement
o 
 
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o 
 
Definitive Proxy Statement
o 
 
Definitive Additional Materials
þ 
 
Soliciting Material Pursuant to §240.14a-12
 
ANIMAS CORPORATION
(Name of Registrant as Specified In Its Charter)
 
JOHNSON & JOHNSON
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check the appropriate box):
þ
 
No fee required.
 
 
 
o
 
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 
1)
 
Title of each class of securities to which transaction applies:
 
 
2)
 
Aggregate number of securities to which transaction applies:
 
 
3)
 
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 
 
4)
 
Proposed maximum aggregate value of transaction:
 
 
5)
 
Total fee paid:
 
o
 
Fee paid previously with preliminary materials.
 
 
 
o
 
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 
 
1)
 
Amount Previously Paid:
 
 
2)
 
Form, Schedule or Registration Statement No.:
 
 
3)
 
Filing Party::
 
 
4)
 
Date Filed:
 
 

 
On January 12, 2006, LifeScan, Inc., an affiliate of Johnson & Johnson, delivered a presentation to employees of Animas Corporation. A copy of the presentation is included below.
 
*****************
 

 
 
Eric Milledge
Company Group Chairman
 
 
 
Founded 1886
New Brunswick, New Jersey
In a Former Wallpaper Factory
By three brothers with a dream… that
Joseph Lister’s theories about sterilization could
save lives in America’s hospitals
 
 
 
 
 
 
Products
Patients & Customers
 
 
 
Global Presence
 
 
 
Global Presence
 
 
 
Strategic Principles
•
Broadly Based in Human Health Care
•
Decentralized Management
•
Manage for the Long Term
•
Ethical Principles
•
Our Credo
 
 
 
Our Credo
•
Written by General Robert
Wood Johnson, Jr. in the
1940s
•
Visionary and U.S. business
leader
•
Among the first to speak
openly of a company’s
responsibility
 
 
 
Our Credo
The Four Tenets
•
Customers
•
Employees
•
Community
•
Shareholders
 
 
 
$47.3B
$8.5B
$2.84
13.1%
18.2%
18.3%
Sales
Net
Earnings
Diluted
EPS
2004 Performance Results
 
 
 
46.7%
17.6%
35.7%
Total Sales: $47.3 Billion
$U.S. Billions
Consumer
$8.3
Medical Devices
& Diagnostics
$16.9
Pharmaceuticals
$22.1
2004 Sales by Segment
 
 
 
23%
59%
6%
12%
Total Sales: $47.3 Billion
Asia, Pacific, Africa
$5.8
W. Hemisphere
$2.6
Europe
$11.1
U.S.
$27.8
$U.S. Billions

  2004 Sales by Geographic Area
 
 
 
(1) Proforma excluding In-process R&D, taxes on repatriated cash under the AJC Act and other charges and credits
100                 +10.6%         +11.0%         +10.7%
50                   +11.1             +11.7            +14.2
20                   +10.9             +10.8            +15.6
10                   +11.8             +12.3            +16.9
  5                   +11.6             +11.1            +16.9
  1                   +13.1               +9.7            +16.8
Reported        Operational             Net
Year                       Sales                 Sales               Income(1)
Historical Performance
 
 
 
(1) Proforma excluding In-process R&D, taxes on repatriated cash under the AJC Act and other charges and credits
Historical Performance
•
72 Consecutive years of Sales
increases
•
20 Consecutive years of double digit
Earnings increases(1)
•
42 Consecutive years of Dividend
increases
 
 
 
$U.S. Billions
9.6%
Percent to Sales
11.0%
Investment in Research
 
 
 
 
 
 
“Creating a world without limits for
people with diabetes”
LifeScan Vision
 
 
 
2004 Sales $1.7B
U.S.             International
Employees                        1,600                                   2,100
Sales Force                          400                                      420
Customer Service                220                                        70
LifeScan At A Glance
 
 
 
$ Billions
Ex U.S.
U.S.
CAGR 8%
5.1
5.7
6.5
8.3
10 .0
Source: LifeScan Estimates, Analyst Reports
Worldwide Glucose
Monitoring Market
 
 
 
LifeScan Key Products
Source: International Diabetes Federation
 
 
 
LifeScan is the #1 Manufacturer
of Test Strips in the U.S.
 
 
 
LifeScan is #1 Recommended by
U.S. Healthcare Professionals
 
 
 
YTD July 2005
LifeScan #1 at U.S. Health Plans
 
 
 
$ Billions
LifeScan Dollar Sales
 
 
 
“To fundamentally change our
business from  measurement to
management, and transform
LifeScan from an episodic
monitoring company to a
true diabetes management
company.”
LifeScan Mission
 
 
 
•
Continued leadership in
Glucose Monitoring
•
Expansion into
Insulin Delivery
•
Creation of Diabetes
Management solutions
Episodic            Continuous
Diabetes
Management
Glucose
Monitoring
Medication
Insulin
Delivery
Our Strategic Direction
 
 
 
 
 
 
Making diabetes management easier through product innovation,
exceptional customer support and customized education programs.
 
 
 
Advancing Care Together
 
 
 
LifeScan Sales & Marketing
•
Direct to Consumer
Marketing
•
Leading in Multi-
Cultural Marketing
•
Best-in-Class Customer
Support
•
Strong CRM Programs
with 3.4M Database
 
 
 
•
Extraordinary talent
•
Entrepreneurship –
intelligent risk taking
•
Collaboration and team
work
•
Passion and sense
of urgency
•
Speed, flexibility, agility
•
Flawless execution
Culture For Success
 
 
 
The Johnson & Johnson Family